Singapore markets closed

Straits Times Index
3,290.70
+24.75(+0.76%)
Nikkei
38,229.11
+155.13(+0.41%)
Hang Seng
18,963.68
+425.87(+2.30%)
FTSE 100
8,433.76
+52.41(+0.63%)
Bitcoin USD
60,885.33
-2,019.28(-3.21%)
CMC Crypto 200
1,261.39
-96.62(-7.11%)

Vera Therapeutics, Inc. (VERA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD

Add to watchlist

41.32

-1.01

(-2.39%)

At close: 04:00PM EDT

41.25

-0.07

(-0.17%)

After hours:

05:33PM EDT

Trade prices are not sourced from all markets

All

GlobeNewswire
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentTopline 96-week data from ORIGIN 2 trial expected in Q4 2024Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment for primary endpoint in Q3 2024; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera The
GlobeNewswire
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera’s 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the
Simply Wall St.
Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week
Key Insights Significantly high institutional ownership implies Vera Therapeutics' stock price is sensitive to their...